$CLVS News Article - Clovis Oncology's Rubraca (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation https://marketwirenews.com/news-releases/clov...35603.html